Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
It's been a big week for immunotherapy for lung cancer. Right on the heels of a press release that the PD-1 inhibitor Opdivo (nivolumab)...
Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and...
Gilotrif (Afatinib) Reports Survival Benefit for EGFR Mutation-Positive Advanced NSCLC: Is it a Superior EGFR Inhibitor?
One of the high profile presentations in the lung cancer track at ASCO 2014 was from Dr. James Yang of a pooled analysis of the LUX-Lung 3 and LUX-...
No Result Found